CFDE Data Portal | Search LOC105377259

	Label	Description
	LOC105377259 Gene (Entity type)	ENSG00000248479 - uncharacterized LOC105377259
	GSE239844 crizotinib 7 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE152699 GSE152723 vemurafenib 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 3 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE168097 epinephrine 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE116133 GSE116136 H-7 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE115395 enzalutamide LNCaP 2 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE128076 doxycycline HEK293 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

LOC105377259

ENSG00000248479 - uncharacterized LOC105377259

GSE239844 crizotinib 7 v 2 human dn

A Gene Set from LINCS

GSE152699 GSE152723 vemurafenib 3 v 1 human up

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 3 v 10 human up

A Gene Set from LINCS

GSE162892 ISOX 3 v 1 human up

A Gene Set from LINCS

GSE168097 epinephrine 3 v 2 human dn

A Gene Set from LINCS

GSE116133 GSE116136 H-7 1 v 0 human up

A Gene Set from LINCS

GSE115395 enzalutamide LNCaP 2 v 3 human up

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 0 v 2 human dn

A Gene Set from LINCS

GSE128076 doxycycline HEK293 1 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.